We are live on ! Find out more
S

Sanofi Portfolio holdings

AUM $336M
1-Year Est. Return 126.85%
This Fund
S&P 500
This Quarter Est. Return
+51.78%
1 Year Est. Return
+126.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$260M
AUM Growth
+$84.6M
Cap. Flow
+$10.7M
Cap. Flow %
4.1%
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
–
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
IMRX icon
Immuneering
IMRX
+$14.1M

Top Sells

Rank Stock Value
1
INZY
Inozyme Pharma
INZY
+$1.77M
2
IGMS
IGM Biosciences
IGMS
+$1.61M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGTX icon
1
MeiraGTx Holdings
MGTX
$1.14B
$100M 38.56%
12,197,737
– –
NVAX icon
2
Novavax
NVAX
$1.23B
$59.7M 22.91%
6,880,481
– –
INBX icon
3
Inhibrx
INBX
$1.21B
$39M 14.98%
1,157,926
– –
ANAB icon
4
AnaptysBio
ANAB
$1.59B
$25.2M 9.67%
821,917
– –
IMRX icon
5
Immuneering
IMRX
$282M
$19M 7.28%
+2,708,559
New +$14.1M
OMDA
6
Omada Health Inc
OMDA
$1.22B
$11.6M 4.46%
524,903
– –
LVTX
7
DELISTED
LAVA Therapeutics
LVTX
$2.99M 1.15%
1,919,455
– –
ELDN icon
8
Eledon Pharmaceuticals
ELDN
$276M
$2.11M 0.81%
814,980
– –
QTTB icon
9
Q32 Bio
QTTB
$452M
$483K 0.19%
244,083
– –
IGMS
10
DELISTED
IGM Biosciences
IGMS
– –
-1,438,975
Closed -$1.61M
INZY
11
DELISTED
Inozyme Pharma
INZY
– –
-443,255
Closed -$1.77M

Similar funds

LFP
Leeward Financial Partners Bellevue, Washington $336M AUM 20.94% 1-Year Est. Return
HFS
Haverford Financial Services Radnor, Pennsylvania $336M AUM 20.46% 1-Year Est. Return
SG
Standard General New York $336M AUM 16.52% 1-Year Est. Return
TH
Team Hewins Redwood City, California $337M AUM 24.42% 1-Year Est. Return
SC
Schiavi & Co Wilmington, Delaware $337M AUM 16.69% 1-Year Est. Return
SIC
Shoker Investment Counsel Oxford, Ohio $337M AUM 24.9% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
PCM
Passive Capital Management Baltimore, Maryland $335M AUM 12.6% 1-Year Est. Return

Sanofi's Q3 2025 Portfolio in Review

As of Q3 2025, Sanofi held 11 positions worth $260M, up 48% from $176M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sanofi deployed $10.7M of net new capital in Q3 2025, opening 1 new position. Its largest new stake was Immuneering: 2,708,559 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Inozyme Pharma, an estimated $1.77M sold.

  • Sanofi's largest Q3 2025 buy was Immuneering: 2,708,559 shares worth $19M.
  • Sanofi fully exited Inozyme Pharma in Q3 2025, selling an estimated $1.77M.
  • Sanofi's ten largest holdings make up 100% of its $260M portfolio in Q3 2025.
  • Sanofi opened 1 new position and closed 2 in Q3 2025.
  • Sanofi's portfolio value rose 48% quarter-over-quarter to $260M.

Based on Sanofi's 13F filing for Q3 2025, filed 4 Nov 2025.